Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pazopanib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    122 result(s) found for: Pazopanib. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2013-003533-16 Sponsor Protocol Number: UMCN-ONCO-201303 Start Date*: 2013-11-21
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Individualizing Pazopanib therapy by exploRing the role of Early metabolic responsE and drug exposure as a preDICTor for treatment outcome in patients with STS
    Medical condition: soft tissue sarcoma patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004404-37 Sponsor Protocol Number: SSGXXI Start Date*: 2011-11-01
    Sponsor Name:Scandinavian Sarcoma Group
    Full Title: Pazopanib in advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib . A non-comparative phase II multicenter study by the Scandinavian Sarcoma Group
    Medical condition: Gatrointestinal stromal tumor (GIST)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DE (Completed) DK (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2005-004078-25 Sponsor Protocol Number: VEG105192 Start Date*: 2006-03-16
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or...
    Medical condition: Locally Advanced and/or metastatic renal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050076 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) SK (Completed) LT (Completed) EE (Completed) AT (Completed) CZ (Completed) IT (Completed) GR (Prematurely Ended) HU (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2011-006085-40 Sponsor Protocol Number: 2011-006085-40 Start Date*: 2012-12-17
    Sponsor Name:Cliniques Universitaires Saint Luc
    Full Title: A proof of concept study to evaluate the use of metabonomics and lipidomics in predicting toxicity and efficacy of anti-VEGF therapy in patients with metastatic clear cell renal cell carcinoma.
    Medical condition: Metastatic clear cell renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000259-17 Sponsor Protocol Number: PazTo_2010 Start Date*: 2012-04-20
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A phase I/II study of Pazopanib and weekly Topotecan in patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer
    Medical condition: This study is a prospective single-arm, open-label, multicenter phase I/II trial. The phase I-trial is a dose-escalation trial to determine the maxium tolerated dose (MTD) of pazopanib in combinati...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001578-32 Sponsor Protocol Number: 2012/49 Start Date*: 2014-11-10
    Sponsor Name:CENTRE ANTOINE LACASSAGNE
    Full Title: A phase I/II study of pazopanib in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and RT-CT (PAZOGLIO study)
    Medical condition: Glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016675-29 Sponsor Protocol Number: RC200902 Start Date*: 2010-04-29
    Sponsor Name:Queen Mary university of London
    Full Title: A Phase II Study Investigating Upfront Pazopanib in Metastatic Clear Cell Renal Cancer [PANTHER]
    Medical condition: Metastatic Renal Cell Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000485-34 Sponsor Protocol Number: 105SAR301 Start Date*: 2017-10-16
    Sponsor Name:TRACON Pharmaceuticals, Inc.
    Full Title: A randomized Phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS)
    Medical condition: Advanced angiosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002476 Angiosarcoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) FR (Completed) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001138-40 Sponsor Protocol Number: IOM-605 Start Date*: 2011-11-17
    Sponsor Name:iOMEDICO AG
    Full Title: First Line Pazopanib in Poor Risk Patients with Metastatic Renal Cell Carcinoma
    Medical condition: Locally advanced or metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022416-40 Sponsor Protocol Number: 3591 Start Date*: 2011-09-30
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A Translational, proof of the concept, study Of Pre-operative Pazopanib in treatment-naive patients with resectable soft tissue Sarcomas (TOPPS)
    Medical condition: Resectable Soft Tisue Sarcomas (cancer of conective soft tissues)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021613-23 Sponsor Protocol Number: Start Date*: 2010-11-24
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: HYPAZ: An open-label investigation into hypertension induced by pazopanib therapy
    Medical condition: Hypertension induced by pazopanib treatment of various cancer types
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001278-26 Sponsor Protocol Number: VEG102857 Start Date*: 2006-10-31
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
    Medical condition: Relaped Malignant Glioma = patients with anaplastic astrocytoma, anaplastic oligodendroglioma, mixed anaplastic oligoastrocytoma, glioblastoma multiforme or gliosarcoma at recurrence
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003785-14 Sponsor Protocol Number: 200249 Start Date*: 2014-03-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK-3475 in Subjects with Advanced Renal Cell Carcinoma
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073251 Clear cell renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002962-11 Sponsor Protocol Number: IQUO/01 Start Date*: 2013-05-24
    Sponsor Name:Interessenverband zur Qualitätsicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland (IQUO) e.V.
    Full Title: Optimizing Pazopanib Exposure in RCC Patients through Therapeutic Drug Monitoring Followed by Intrapatient Dose Escalation
    Medical condition: Renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-017328-25 Sponsor Protocol Number: PACOVAR Start Date*: 2010-10-18
    Sponsor Name:University Hospital Heidelberg
    Full Title: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer
    Medical condition: This study is a prospective open-label, non-randomized multicenter phase I/II trial in order to determine overall response rate of patients with platinum-resistant or refractory recurrent, pretreat...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004108-20 Sponsor Protocol Number: UMCN-AKF13.05 Start Date*: 2014-03-17
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Improving the tolerability of the oral targeted anti-cancer drug pazopanib by food intake (DIET)
    Medical condition: Patients who are treated or will be treated with pazopanib.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073145 Soft tissue cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005954-22 Sponsor Protocol Number: VEG108843 Start Date*: 2008-06-03
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A randomized, double-blind, placebo-controlled, multicenter Phase II study to compare the efficacy and tolerability of pazopanib administered in combination with exemestane versus exemestane plus p...
    Medical condition: Advanced or metastatic hormone receptor positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003810-15 Sponsor Protocol Number: PazoDoble Start Date*: 2013-12-20
    Sponsor Name:NOGGO e.V.
    Full Title: Pazopanib versus Pazopanib plus Gemcitabine in patients with relapsed or metastatic uterine leiomyosarcomas or other uterine tumour: a multi-center, randomized phase-II clinical trial of the NOGGO ...
    Medical condition: This study is a prospective, randomized, open-label, multicenter phase II trial in order to determine progression-free survival of patients with refractory or relapsed metastatic uterine leiomyosar...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007508 Carcinosarcoma uterus LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046799 Uterine leiomyosarcoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000143-26 Sponsor Protocol Number: VEG105290 Start Date*: 2006-06-06
    Sponsor Name:GlaxoSmithkline S.A.
    Full Title: A Phase II, Non-randomized, Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Pre-Surgical Therapy in Treatment-Naïve Subjects with Stage IA or IB, Resectable Non Sma...
    Medical condition: Resectable NonSmall Cell Lung Cancer, Stage IA/IB
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-005252-21 Sponsor Protocol Number: N17PSI Start Date*: 2017-04-13
    Sponsor Name:Netherlands Cancer Institute
    Full Title: Increasing pazopanib exposure by splitting intake moments
    Medical condition: Patients for whom pazopanib is considered standard care (advanced renal cell carcinoma and advanced soft-tissue sarcoma).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 08:16:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA